Richard W. Pascoe has been the Chief Executive Officer and a director of Histogen since January 2019, and served as Chairman from January 2019 to May 2020.
Mr. Pascoe joined the Company following the merger of Apricus Biosciences Inc. and Seelos Therapeutics, Inc. Mr. Pascoe was the Chief Executive Officer of Apricus from March 2013 until joining the Company. Prior to Apricus, Mr. Pascoe was with Somaxon Pharmaceuticals, Inc. where he served as the Chief Executive Officer.
Prior to joining Somaxon in 2008, Mr. Pascoe served as Chief Operating Officer at ARIAD Pharmaceuticals, Inc. Prior to ARIAD, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.), including Senior Vice President positions in King’s international and hospital commercial business units. Prior to King, Mr. Pascoe held commercial roles in the hospital pharmaceutical and medical device groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc.), and B. Braun Interventional.
Mr. Pascoe is a member of the board of directors of KemPharm, Inc., as well as a member of the company’s audit and compensation committees and its lead independent director. He also serves as a member of the board of directors of Seelos Therapeutics, Inc. where he chairs the audit committee. He is also a member of the board of directors of Biocom, California’s leading advocate for the life sciences industry, and the Johnny Mac Soldiers Fund, a charity for military veterans.
Mr. Pascoe served on active duty as a Commissioned Officer with the U.S. Army’s 24th Infantry Division to include one combat tour in Iraq earning several awards and decorations including the Bronze Star Medal. He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership. Mr. Pascoe is currently serves as the Civilian Aide to the Secretary of the Army for Southern California, where he serves as a volunteer liaison between the Secretary and the local community.
What is Richard W. Pascoe's net worth?
The estimated net worth of Richard W. Pascoe is at least $5.99 as of March 9th, 2023. Mr. Pascoe owns 29,973 shares of Histogen stock worth more than $6 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Pascoe may own. Learn More about Richard W. Pascoe's net worth.
How do I contact Richard W. Pascoe?
Has Richard W. Pascoe been buying or selling shares of Histogen?
Richard W. Pascoe has not been actively trading shares of Histogen within the last three months. Most recently, on Tuesday, March 30th, Richard W. Pascoe bought 20,000 shares of Histogen stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $22,800.00. Following the completion of the transaction, the chief executive officer now directly owns 30,000 shares of the company's stock, valued at $34,200. Learn More on Richard W. Pascoe's trading history.
